CSL signs U.S. government agreements to lower drug prices for Medicaid
Reuters2026/08/31 22:28- CSL signed agreements with the US government to lower US drug prices, including Medicaid pricing comparable to other developed countries.
- Newly launched therapies will be similarly priced across all US payers under the Health and Human Services agreement.
- An Onshoring Agreement with the Commerce Department supports a USD 1.5 billion Illinois manufacturing expansion, creating at least 300 jobs.
- The deals add certainty on US pricing exposure, including some Section 232 tariffs, with no expected material impact in fiscal 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Global bond yields rise to highest level in two decades as oil prices and inflation fears rattle markets
Strong demand for cardiac devices drives Medtronic (MDT.US) to exceed Q1 expectations and raise full-year guidance; invests $700 million to expand robotic surgery business.
Medical device manufacturer Medtronic reported better-than-expected results for the first quarter of fiscal year 2027 and raised its full-year guidance, betting on strong demand for its cardiac devices used in complex cardiovascular surgeries.
Kast launches stablecoin-powered business platform after $80M raise
Vertex names Jonathan Poole CFO effective Jan. 1, 2027
Crypto prices
More
